Free Trial

Stevanato Group S.p.A. (NYSE:STVN) Receives Consensus Rating of "Moderate Buy" from Analysts

Stevanato Group logo with Medical background

Shares of Stevanato Group S.p.A. (NYSE:STVN - Get Free Report) have earned an average recommendation of "Moderate Buy" from the six ratings firms that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company.

A number of brokerages recently issued reports on STVN. Bank of America increased their target price on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, December 13th. Morgan Stanley reaffirmed an "equal weight" rating and set a $23.00 price objective (down previously from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. Finally, Wolfe Research started coverage on Stevanato Group in a report on Friday, December 13th. They issued an "outperform" rating and a $28.00 target price on the stock.

Check Out Our Latest Report on STVN

Stevanato Group Stock Performance

Shares of STVN traded up €0.30 ($0.31) during mid-day trading on Tuesday, hitting €24.04 ($24.78). The company's stock had a trading volume of 248,400 shares, compared to its average volume of 305,425. Stevanato Group has a one year low of €16.56 ($17.07) and a one year high of €34.73 ($35.80). The stock's 50-day moving average is €20.98 and its two-hundred day moving average is €20.11. The firm has a market capitalization of $7.10 billion, a PE ratio of 51.15, a price-to-earnings-growth ratio of 10.49 and a beta of 0.56. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81.

Stevanato Group (NYSE:STVN - Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported €0.12 ($0.12) earnings per share for the quarter, missing the consensus estimate of €0.13 ($0.13) by (€0.01) (($0.01)). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The company had revenue of €277.90 million during the quarter, compared to the consensus estimate of €274.36 million. During the same quarter in the previous year, the business posted $0.16 EPS. The firm's quarterly revenue was up 2.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Stevanato Group will post 0.5 EPS for the current year.

Hedge Funds Weigh In On Stevanato Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in STVN. Natixis Advisors LLC raised its holdings in shares of Stevanato Group by 27.3% in the second quarter. Natixis Advisors LLC now owns 42,674 shares of the company's stock valued at $783,000 after purchasing an additional 9,146 shares during the last quarter. TD Asset Management Inc grew its holdings in shares of Stevanato Group by 324.2% in the 2nd quarter. TD Asset Management Inc now owns 108,853 shares of the company's stock valued at $1,996,000 after acquiring an additional 83,191 shares in the last quarter. Thornburg Investment Management Inc. increased its position in shares of Stevanato Group by 279.1% in the second quarter. Thornburg Investment Management Inc. now owns 746,218 shares of the company's stock valued at $13,690,000 after acquiring an additional 549,378 shares during the last quarter. Oppenheimer Asset Management Inc. raised its holdings in Stevanato Group by 59.2% during the second quarter. Oppenheimer Asset Management Inc. now owns 11,941 shares of the company's stock worth $219,000 after acquiring an additional 4,441 shares in the last quarter. Finally, Blair William & Co. IL acquired a new position in Stevanato Group during the second quarter valued at approximately $387,000.

About Stevanato Group

(Get Free Report

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.

Further Reading

Analyst Recommendations for Stevanato Group (NYSE:STVN)

Should You Invest $1,000 in Stevanato Group Right Now?

Before you consider Stevanato Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stevanato Group wasn't on the list.

While Stevanato Group currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Affordable AI Stocks: 7 Picks Under $50
2025 Natural Gas Comeback: 3 Stocks Poised for Big Gains
Why the Latest Jobs Data Has Wall Street Nervous

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines